Your browser doesn't support javascript.
loading
Prescription medication use as a risk factor for motor vehicle collisions: a responsibility study.
Asbridge, Mark; Macnabb, Kathleen; Chan, Herbert; Erdelyi, Shannon; Wilson, Maria; Brubacher, Jeffrey R.
Afiliação
  • Asbridge M; Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada mark.asbridge@dal.ca.
  • Macnabb K; Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Chan H; Department of Emergency Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Erdelyi S; Department of Emergency Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Wilson M; Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Brubacher JR; Department of Emergency Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
Inj Prev ; 27(4): 324-330, 2021 08.
Article em En | MEDLINE | ID: mdl-32732340
ABSTRACT

INTRODUCTION:

Previous studies on the effect of prescription medications on MVCs are sparse, not readily applicable to real-world driving and/or subject to strong selection bias. This study examines whether the presence of prescription medication in drivers' blood is associated with being responsible for MVC.

METHODS:

This modified case-control study with responsibility analysis compares MVC responsibility rates among drivers with detectable levels of six classes of prescription medications (anticonvulsants, antidepressants, antihistamines, antipsychotics, benzodiazepines, opioids) versus those without. Data were collected between January 2010 and July 2016 from emergency departments in British Columbia, Canada. Collision responsibility was assessed using a validated and automated scoring of police collision reports. Multivariable logistic regression was used to determine OR of responsibility (analysed in 2018-2019).

RESULTS:

Unadjusted regression models show a significant association between anticonvulsants (OR 1.92; 95% CI 1.20 to 3.09; p=0.007), antipsychotics (OR 5.00; 95% CI 1.16 to 21.63; p=0.03) and benzodiazepines (OR 2.99; 95% CI 1.56 to 5.75; p=0.001) with collision responsibility. Fully adjusted models show a significant association between benzodiazepines with collision responsibility (aOR 2.29; 95% CI 1.16 to 4.53; p=0.02) after controlling for driver characteristics, blood alcohol and Δ-9-tetrahydrocannabinol concentrations, and the presence of other prescription medications. Antidepressants, antihistamines and opioids exhibited no significant associations.

CONCLUSION:

There is a moderate increase in the risk of a responsible collision among drivers with detectable levels of benzodiazepines in blood. Physicians and pharmacists should consider collision risk when prescribing or dispensing benzodiazepines. Public education about benzodiazepine use and driving and change to traffic policy and enforcement measures are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Condução de Veículo / Acidentes de Trânsito Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Condução de Veículo / Acidentes de Trânsito Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article